Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iñaki F Troconiz

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Pharmaceutics|January 25, 2025
Development and Application of Physiologically-Based Pharmacokinetic Model to Predict Systemic and Organ Exposure of Colorectal Cancer DrugsSara Peribañez-Dominguez, Zinnia Parra-Guillen, Iñaki F Troconiz
Clinical and Translational Science|February 12, 2020
Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic CancerMaria Garcia-Cremades, Nicola Melillo, Iñaki F Troconiz, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 29, 2016
Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response ModelMaria Garcia-Cremades, Celine Pitou, Philip W Iversen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 26, 2018
Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancerMaria Garcia-Cremades, Celine Pitou, Philip W Iversen, et al.
The AAPS Journal|February 2, 2019
Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft StudiesMaria Garcia-Cremades, Celine Pitou, Philip W Iversen, et al.
Frontiers in Pharmacology|September 29, 2023
A physiologically based pharmacokinetic model for V937 oncolytic virus in miceSara Peribañez-Dominguez, Zinnia P Parra-Guillen, Tomoko Freshwater, et al.
Clinical Pharmacology and Therapeutics|July 22, 2024
Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and PembrolizumabAymara Sancho-Araiz, Zinnia P Parra-Guillen, Iñaki F Troconiz, et al.
Clinical Pharmacology and Therapeutics|September 29, 2019
Model-Informed Dose Selection for Xentuzumab, a Dual Insulin-Like Growth Factor-I/II-Neutralizing AntibodyZinnia P Parra-Guillen, Ulrike Schmid, Alvaro Janda, et al.
British Journal of Clinical Pharmacology|March 1, 2016
Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its O-demethyl metabolite on pupil diameter and nociception in healthy subjectsVíctor Mangas-Sanjuan, José Martín Pastor, Jens Rengelshausen, et al.
The AAPS Journal|April 23, 2013
Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategiesZinnia P Parra-Guillen, Pedro Berraondo, Emmanuel Grenier, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Pharmaceutics|January 25, 2025
Development and Application of Physiologically-Based Pharmacokinetic Model to Predict Systemic and Organ Exposure of Colorectal Cancer DrugsSara Peribañez-Dominguez, Zinnia Parra-Guillen, Iñaki F Troconiz
Clinical and Translational Science|February 12, 2020
Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic CancerMaria Garcia-Cremades, Nicola Melillo, Iñaki F Troconiz, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 29, 2016
Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response ModelMaria Garcia-Cremades, Celine Pitou, Philip W Iversen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 26, 2018
Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancerMaria Garcia-Cremades, Celine Pitou, Philip W Iversen, et al.
The AAPS Journal|February 2, 2019
Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft StudiesMaria Garcia-Cremades, Celine Pitou, Philip W Iversen, et al.
Frontiers in Pharmacology|September 29, 2023
A physiologically based pharmacokinetic model for V937 oncolytic virus in miceSara Peribañez-Dominguez, Zinnia P Parra-Guillen, Tomoko Freshwater, et al.
Clinical Pharmacology and Therapeutics|July 22, 2024
Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and PembrolizumabAymara Sancho-Araiz, Zinnia P Parra-Guillen, Iñaki F Troconiz, et al.
Clinical Pharmacology and Therapeutics|September 29, 2019
Model-Informed Dose Selection for Xentuzumab, a Dual Insulin-Like Growth Factor-I/II-Neutralizing AntibodyZinnia P Parra-Guillen, Ulrike Schmid, Alvaro Janda, et al.
British Journal of Clinical Pharmacology|March 1, 2016
Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its O-demethyl metabolite on pupil diameter and nociception in healthy subjectsVíctor Mangas-Sanjuan, José Martín Pastor, Jens Rengelshausen, et al.
The AAPS Journal|April 23, 2013
Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategiesZinnia P Parra-Guillen, Pedro Berraondo, Emmanuel Grenier, et al.
Pageof 4